Y Intercept Hong Kong Ltd Buys Shares of 19,001 Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Y Intercept Hong Kong Ltd purchased a new position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 19,001 shares of the company’s stock, valued at approximately $111,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Conway Capital Management Inc. purchased a new stake in Olema Pharmaceuticals during the 3rd quarter worth about $119,000. Vontobel Holding Ltd. acquired a new stake in shares of Olema Pharmaceuticals during the 4th quarter worth about $62,000. Portland Investment Counsel Inc. purchased a new stake in shares of Olema Pharmaceuticals during the third quarter worth about $143,000. Intech Investment Management LLC acquired a new position in shares of Olema Pharmaceuticals in the third quarter valued at approximately $163,000. Finally, SG Americas Securities LLC lifted its stake in shares of Olema Pharmaceuticals by 33.8% during the fourth quarter. SG Americas Securities LLC now owns 17,475 shares of the company’s stock valued at $102,000 after buying an additional 4,419 shares during the period. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, major shareholder Bain Capital Life Sciences Inv bought 300,000 shares of Olema Pharmaceuticals stock in a transaction that occurred on Wednesday, January 8th. The shares were purchased at an average price of $5.76 per share, for a total transaction of $1,728,000.00. Following the completion of the acquisition, the insider now owns 7,800,000 shares of the company’s stock, valued at $44,928,000. The trade was a 4.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Cyrus Harmon sold 8,256 shares of the business’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $9.37, for a total value of $77,358.72. Following the sale, the director now directly owns 772,277 shares of the company’s stock, valued at approximately $7,236,235.49. This trade represents a 1.06 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 773,797 shares of company stock valued at $5,414,609. Insiders own 19.40% of the company’s stock.

Olema Pharmaceuticals Price Performance

OLMA opened at $4.26 on Thursday. The stock has a market capitalization of $244.09 million, a price-to-earnings ratio of -1.95 and a beta of 2.05. Olema Pharmaceuticals, Inc. has a 12 month low of $4.07 and a 12 month high of $16.62. The business has a 50-day moving average of $5.42 and a two-hundred day moving average of $8.96.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Olema Pharmaceuticals in a research note on Wednesday.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.